N-(9-Fluorenylmethoxycarbonyl)-L-Phenylalanine/nano-hydroxyapatite hybrid supramolecular hydrogels as drug delivery vehicles with antibacterial property and cytocompatibility

Wan, Li; Hu, Xueying; Chen, Jiawei; Wei, Zuoan; Song, Chengwu; Huang, Rongzeng

doi:10.1007/s10856-020-06410-9

Cited by 14 publications

(11 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As shown in Table 1 , compared with the four kinds of kinetic equations, both Rhy and Rhy-SLNs had the highest R-squared value in the Weibull model kinetic equation. The value of the exponent β is an indicator of the mechanism of transport of a drug through the matrix [ 25 ]. According to the Weibull model, the value of β was 0.4966 or 0.49122 (β ≤ 0.75), suggesting the Fickian diffusion mechanism [ 34 ].…”

Section: Resultsmentioning

confidence: 99%

“…Then, the zero-order model, the first-order model, the Higuchi model, the Ritger-Peppas model, and the Weibull model were used to model the Rhy and Rhy-SLNs release kinetics as previously described [ 25 , 26 ]. Zero-order model: Q 0 – Q t = kt; First-order model: lnQ 0 – lnQ t = kt; Higuchi model: Q 0 – Q t = kt 1/2 ; Ritger-Peppas: Q 0 – Q t = kt n ; Weibull model: Q 0 – Q t = 1 – exp(-kt β ).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Solid lipid nanoparticle delivery of rhynchophylline enhanced the efficiency of allergic asthma treatment via the upregulation of suppressor of cytokine signaling 1 by repressing the p38 signaling pathway

Li²,

Cui

et al. 2021

Bioengineered

View full text Add to dashboard Cite

Allergic asthma is one of the most common chronic airway diseases, and there is still a lack of effective drugs for the treatment of allergic asthma. The purpose of this work is to formulate rhynchophylline (Rhy)-solid lipid nanoparticles (SLNs) to improve their therapeutic efficacy in a mice allergic model of asthma. A solvent injection method was employed to prepare the Rhy-SLNs. Physicochemical characterization of Rhy-SLNs was measured, and the release assessment was investigated, followed by the release kinetics. Next, a model of murine experimental asthma was established. Mice were subcutaneously injected with 20 μg ovalbumin mixed with 1 mg aluminum hydroxide on days 0, 14, 28, and 42 and administrated aerosolized 1% ovalbumin (w/v) by inhalation from day 21 to day 42. Mice were intraperitoneally injected with 20 mg/kg Rhy-SLNs or Rhy at one hour before the airway challenge with ovalbumin. The results showed that Rhy-SLNs revealed a mean particle size of 62.06 ± 1.62 nm with a zeta potential value of -6.53 ± 0.04 mV and 82.6 ± 1.8% drug entrapment efficiency.The release curve of Rhy-SLNs was much higher than the drug released in phosphate buffer saline at 0, 1, 1.5, 2, 4, or 6 h. Moreover, Rhy-SLNs exerted better effects on inhibiting ovalbumin-induced airway inflammation, oxidative stress, airway remodeling (including collagen deposition and mucus gland hyperplasia) than Rhy in murine experimental asthma. Subsequently, we found that Rhy-SLNs relieved allergic asthma via the upregulation of the suppressor of cytokine signaling 1 by repressing the p38 signaling pathway.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Solid lipid nanoparticle delivery of rhynchophylline enhanced the efficiency of allergic asthma treatment via the upregulation of suppressor of cytokine signaling 1 by repressing the p38 signaling pathway

Li²,

Cui

et al. 2021

Bioengineered

View full text Add to dashboard Cite

show abstract

“…73 Li et al further incorporated 0.1 wt % nanohydroxyapatite (nHAp) to reinforce the supramolecular Fmoc-Phe-OH hydrogel network, which enhanced the compressive modulus from 0.45 to 0.72. 74 The addition of nHAp did not affect the inherent antibacterial properties of the hydrogel, in which 64.77% of the loaded antibiotic was released over a 12 h period under first-order kinetic control. Benedini and co-workers also employed nHAp and encapsulated ciprofloxacin (CIP) in alginate-based (Alg-based) hydrogels.…”

Section: Hydrogel-based Strategy For Osteomyelitis Treatmentmentioning

confidence: 99%

Hydrogel-Based Strategies for the Management of Osteomyelitis

Kuo

Lin

Yeh

2023

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Osteomyelitis is a type of bone infection caused by bacteria, with Staphylococcus sepsis being responsible for most cases. Osteomyelitis treatment generally requires a multifaceted approach that may include intervention of surgery and administration of antibacterial agents, where several materials have been utilized as delivery vehicles for antibiotics and other antibacterial materials. Hydrogel has become a popular candidate for osteomyelitis treatment due to its biocompatibility, water-containing porous structure, and adaptable physicochemical properties. In this review, we discuss several hydrogel-based strategies for osteomyelitis treatment and categorized them based on the encapsulated cargos (i.e., antibiotics, silver nanoparticles, protein and bacteriophage, and reactive oxygen species (ROS) generator). Several representative examples of osteomyelitis treatment using hydrogels are described here, focusing on their design, preparation, properties, and outcomes. We also provide our perspectives on the remaining concerns regarding fabricating advanced hydrogels for osteomyelitis treatment. This review will be valuable to the hydrogel community and inspire researchers to develop next-generation hydrogels for specific and practical clinical applications in osteomyelitis.

show abstract

“…Several works explored peptides‐based supramolecular hydrogels in controlled drug delivery, including hydrogels of tripeptide derivatives, [117a] Arg−Gly−Asp (RGD)‐derived peptide conjugate, [117b] PEG‐block‐poly(L‐alanine‐co‐glycine‐co‐L‐isoleucine), [117c] peptide nanofiber, [117d] myristyl‐Phe‐Phe amphiphile nanofiber, [117e] H 2 O 2 ‐responsive peptide hydrogelator bearing thiazolidinone group, [117f] hydrogels of low molecular weight cationic derivative of phenylalanine, [117g] dehydropeptide hydrogelator, [117h] and fluorenylmethoxycarbonyl)‐L‐phenylalanine [117i,j] …”

Section: Supramolecular Gelsmentioning

confidence: 99%

Recent Updates on Supramolecular‐Based Drug Delivery – Macrocycles and Supramolecular Gels

Saji

2022

The Chemical Record

View full text Add to dashboard Cite

Supramolecules‐based drug delivery has attracted significant recent research attention as it could enhance drug solubility, retention time, targeting, and stimuli responsiveness. Among the different supramolecules and assemblies, the macrocycles and the supramolecular hydrogels are the two important categories investigated to a greater extent. Here, we provide the most recent advancements in these categories. Under macrocycles, reports on drug delivery by cyclodextrins, cucurbiturils, calixarenes/pillararenes, crown ethers and porphyrins are detailed. The second category discusses the supramolecular hydrogels of macrocycles/polymers and low molecular weight gelators. The updated information provided could be helpful to advance R & D in this vital area.

show abstract

N-(9-Fluorenylmethoxycarbonyl)-L-Phenylalanine/nano-hydroxyapatite hybrid supramolecular hydrogels as drug delivery vehicles with antibacterial property and cytocompatibility

Cited by 14 publications

References 48 publications

Solid lipid nanoparticle delivery of rhynchophylline enhanced the efficiency of allergic asthma treatment via the upregulation of suppressor of cytokine signaling 1 by repressing the p38 signaling pathway

Solid lipid nanoparticle delivery of rhynchophylline enhanced the efficiency of allergic asthma treatment via the upregulation of suppressor of cytokine signaling 1 by repressing the p38 signaling pathway

Hydrogel-Based Strategies for the Management of Osteomyelitis

Recent Updates on Supramolecular‐Based Drug Delivery – Macrocycles and Supramolecular Gels

Contact Info

Product

Resources

About